This paper evaluates unanticipated (off-target or pleiotropic) effects of GLP-1 receptor agonists (GLP-1 RAs) beyond their primary indications of glycemic control and weight loss.
The authors conclude that the unanticipated effects of GLP-1 RAs represent a net positive, suggesting benefits across multiple organ systems or disease domains beyond the originally intended metabolic targets.
The source text provides only the title and metadata; specific study design, sample sizes, individual findings, and supporting data cannot be verified from the available text.
Clinicians should be aware that GLP-1 RAs may carry meaningful benefits beyond weight and glucose management, though the full scope of these effects requires review of the complete publication.
Explore related topics
